前列腺MRI PI-RADS 2.1版诊断性能基准更新:系统综述与Meta分析
该系统综述与Meta分析纳入70项研究(11686个病灶、13330例患者),评估PI-RADS 2.1版对临床显著前列腺癌的诊断准确性和各分类的癌症检出率。患者水平以PI-RADS≥3为阳性时汇总敏感度96%、特异度43%,以PI-RADS≥4为阳性时敏感度89%、特异度66%;PI-RADS 1至5的癌症检出率分别为6%、5%、19%、54%和84%。
要点
- 患者水平PI-RADS≥3为阳性时汇总敏感度96%(95%CI 95,98)、特异度43%(95%CI 33,54)。
- 患者水平PI-RADS≥4为阳性时汇总敏感度89%(95%CI 85,92)、特异度66%(95%CI 58,74)。
- PI-RADS 1至5的癌症检出率分别为6%、5%、19%、54%和84%。
核心结论
- 提供了PI-RADS 2.1版各分类的诊断准确性和癌症检出率估计,用于质量基准对标并指导进一步的循证患者管理。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase、Cochrane Library及多个试验注册库,纳入2019年3月1日至2022年8月30日发表的英文研究,共70项研究(11686个病灶、13330例患者),以临床显著前列腺癌为主要结局,在病灶水平和患者水平提取数据。
诊断标准与关键数值
- 患者水平以PI-RADS≥3为阳性:汇总敏感度96%(95%CI 95,98)、特异度43%(95%CI 33,54),SROC曲线下面积0.86(95%CI 0.75,0.93);以PI-RADS≥4为阳性:汇总敏感度89%(95%CI 85,92)、特异度66%(95%CI 58,74),SROC曲线下面积0.89(95%CI 0.85,0.92)。癌症检出率:PI-RADS 1为6%、PI-RADS 2为5%、PI-RADS 3为19%、PI-RADS 4为54%、PI-RADS 5为84%;移行带2+1病灶癌症检出率12%(95%CI 7,19),3+0病灶19%(95%CI 12,29),两者比较P=.12。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Prostate MRI for the detection of clinically significant prostate cancer (csPCa) is standardized by the Prostate Imaging Reporting and Data System (PI-RADS), currently in version 2.1. A systematic review and meta-analysis infrastructure with a 12-month update cycle was established to evaluate the diagnostic performance of PI-RADS over time. Purpose To provide estimates of diagnostic accuracy and cancer detection rates (CDRs) of PI-RADS version 2.1 categories for prostate MRI, which is required for further evidence-based patient management. Materials and Methods A systematic search of PubMed, Embase, Cochrane Library, and multiple trial registers (English-language studies published from March 1, 2019, to August 30, 2022) was performed. Studies that reported data on diagnostic accuracy or CDRs of PI-RADS version 2.1 with csPCa as the primary outcome were included. For the meta-analysis, pooled estimates for sensitivity, specificity, and CDRs were derived from extracted data at the lesion level and patient level. Sensitivity and specificity for PI-RADS greater than or equal to 3 and PI-RADS greater than or equal to 4 considered as test positive were investigated. In addition to individual PI-RADS categories 1-5, subgroup analyses of subcategories (ie, 2+1, 3+0) were performed. Results A total of 70 studies (11 686 lesions, 13 330 patients) were included. At the patient level, with PI-RADS greater than or equal to 3 considered positive, meta-analysis found a 96% summary sensitivity (95% CI: 95, 98) and 43% specificity (95% CI: 33, 54), with an area under the summary receiver operating characteristic (SROC) curve of 0.86 (95% CI: 0.75, 0.93). For PI-RADS greater than or equal to 4, meta-analysis found an 89% sensitivity (95% CI: 85, 92) and 66% specificity (95% CI: 58, 74), with an area under the SROC curve of 0.89 (95% CI: 0.85, 0.92). CDRs were as follows: PI-RADS 1, 6%; PI-RADS 2, 5%; PI-RADS 3, 19%; PI-RADS 4, 54%; and PI-RADS 5, 84%. The CDR was 12% (95% CI: 7, 19) for transition zone 2+1 lesions and 19% (95% CI: 12, 29) for 3+0 lesions (P = .12). Conclusion Estimates of diagnostic accuracy and CDRs for PI-RADS version 2.1 categories are provided for quality benchmarking and to guide further evidence-based patient management. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Tammisetti and Jacobs in this issue.
引用
- Oerther B, Nedelcu A, Engel H, et al. Update on PI-RADS Version 2.1 Diagnostic Performance Benchmarks for Prostate MRI: Systematic Review and Meta-Analysis. Radiology. 2024. PMID: 39136561. doi:10.1148/radiol.233337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。